Skip to main content

Table 1 Baseline demographic and laboratory data

From: Usefulness of glycated albumin as a predictor of mortality in chronic hemodialysis patients with diabetes: a multi-center, prospective cohort study

 Overall (n = 841)
Age64 ± 11 years
Men606 (72.1%)
Dialysis vintage4.5 years (2.4–7.9)
Type 1 diabetes75 (8.9%)
Diabetes therapy
 Insulin344 (40.9%)
 Other medication369 (43.9%)
 ACE inhibitors or ARBs552 (65.6%)
 Other antihypertensive drugs600 (71.3%)
 Statins272 (32.3%)
 History of ASCVD333 (39.6%)
 Current smoker168 (20.0%)
 Body mass index23.5 ± 4.0 kg/m2
 SBP154 ± 23 mmHg
 DBP78 ± 13 mmHg
Laboratory data
 GA21.4 ± 5.0%
 HbA1c6.4 ± 1.1%
 Glucose145 ± 55 mg/dL
 Hemoglobin10.8 ± 1.1 g/dL
 Albumin3.6 ± 0.3 g/dL
 Urea nitrogen59.3 ± 15.2 mg/dL
 Creatinine10.5 ± 2.6 mg/dL
 Potassium4.9 ± 0.7 mEq/L
 Corrected calcium9.5 ± 0.7 mg/dL
 Phosphate5.6 ± 1.4 mg/dL
 HDL cholesterol45 ± 15 mg/dL
 Non-HDL cholesterol109 ± 32 mg/dL
  1. Data are expressed as mean (standard deviation), median (interquartile range), or number (percentage)
  2. ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, ASCVD atherosclerotic cardiovascular disease, SBP systolic blood pressure, DBP diastolic blood pressure, GA glycated albumin, HbA1c hemoglobin A1c, HDL high-density lipoprotein